Investors, Press

23 November 2016 – Invitrocue (ASX:IVQ) is pleased to announce that Dr. Ramanuj DasGupta, Ph.D will be joining the company as Senior Scientific Director on 1 December 2016. Dr. DasGupta is a highly regarded professor in New York University School of Medicine with more than a decade of experience in cancer research and drug discovery. In March 2016, his proprietary compounds were licensed to iβeCa Therapeutics, a spin-off which is venture-funded by Allied-Bristol Life Sciences.

In 2014, Dr. DasGupta joined the Genome Institute of Singapore, A*STAR as a Senior Investigator, where he established the Centre for High-throughput Phenomics and the Perkin Elmer-GIS Joint Centre for Precision Oncology to develop new evidence-based paradigms for the treatment of cancers.

“Dr. DasGupta is a talented reseacher who brings to Invitrocue substantial scientific experience in oncology from discovery through to commercial development,” said Dr. Steven Fang, Executive Director. “We look forward to his contributions to our senior management team as we aggressively pursue the development of our Onco-PDO™ personalised drug screening technology.”

“This is an exciting time for Invitrocue with its many promising commercial opportunities,” said Dr. DasGuta. “I am excited to join a team with such strong technology credentials, and I look forward to contributing to the Company’s future success.”

Dr. DasGupta is the recipient of several national and international awards such as the Harold Weintraub award, Breast Cancer Research Foundation Concept Award (USA), NYSTEM Idea Award, ACS Research Scholar Award (USA), March of Dimes Research Grant, the NYC BioAccelerate Prize, and the Wellcome Trust International Senior Research Fellowship, amongst others.

 

– ENDS –

 

 

For more information, please contact:

Matthew Gregorowski, Citadel-MAGNUS

T: +61 2 8234 0100

mgregorowski@citadelmagnus.com

 

About Invitrocue

Invitrocue is a leading healthcare bio-analytic solutions including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

Invitrocue currently operates in Singapore and China and is listed on Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com